Now playing…

“Immunotherapy and Advanced Prostate Cancer”
produced with generous support from Bavarian Nordic
Nicholas J. Vogelzang, MD 
is a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN) and serves as chair and site research leader, and as medical director of the Developmental Therapeutics Committee and Member of the Genitourinary Committee for US Oncology Research.  Dr. Vogelzang  is questioned by Joel Nowak, MSW, MS, Director, Advocacy and Advanced Stage Disease at Malecare.

Follow along by reading the TRANSCRIPT (transcript will open in a seperate window)

0:00

 

“Bone Health and Prostate Cancer”
 produced with generous support from Bayer 
Dr. Neal Shore serves as Medical Director for the Carolina Urologic Research Center and is in practice at the Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 250 clinical trials, focusing mainly on prostate and bladder disease, and serves on the boards of several academic and advocacy networks.  Dr. Shore is questioned by Joel Nowak, MSW, MS, Director, Advocacy and Advanced Stage Disease at Malecare.

Follow along by reading the TRANSCRIPT (transcript will open in a separate window)

0:00

“New Prostate Cancer Tests”

Dr. Daniel Lieber and Dr. Steve Hershman are interviewed about the latest genomic tests for prostate cancer.  Both Dr. Lieber and Dr. Hershman are PhD graduates of Harvard University System Biology program.  They are interviewed by Joel Nowak,  MSW, Director of Malecare Advanced Disease and Advocacy.

Follow along by reading the TRANSCRIPT (transcript will open in a separate window)

0:00

“All About New Options for Men with Advanced Prostate Cancer – Treatments, Immunotherapy & Clinical Trials”

James L. Gulley, M.D., Ph.D., F.A.C.P. is Director, Clinical Trials Group and Deputy Chief, Laboratory of Tumor Immunology and Biology as well as the Senior Investigator iin the Medical Oncology Branch of the Center for Cancer Research, National Cancer Institute National Institutes of Health. He is interviewed by Joel Nowak, MSW, Director of Malecare Advanced Disease and Advocacy. This teleconference presents an overview of the new treatments now available for men with castrate resistant advanced prostate cancer including a discussion of the sequencing and combining of these treatments.  They also talk about immunotherapies and their role in current treatment.
Follow along by reading the TRANSCRIPT (transcript will open in a separate window)

0:00

 

“All About Provenge”
Joel Nowak, MA, MSW, Director of Malecare Advanced Disease and Advocacy will be speaking with Neal Shore, MD. Dr. Shore is affiliated with the Carolina Urologic Research Center, Linked Urology Research Network and Uropath and is using Provenge with advanced prostate cancer patients.
Follow along by reading the TRANSCRIPT (transcript will open in a separate window)

0:00

“All About Advanced Prostate Cancer”

Dr. McKiernan is Vice Chairman of the Department and Director of Urologic Oncology at New York – Presbyterian Hospital/Columbia University Medical Center. He treats many patients with high risk cancer diagnoses. He is interviewed by Joel Nowak, MSW, Director of Malecare Advanced Disease and Advocacy

Dr. McKiernan is actively involved with ongoing research programs focused on improving patient outcomes. He has authored and co-authored more than 80 articles, book chapters, and abstracts in the field of urologic oncology. His research and discoveries have been published in Urology, Journal of Urology, Journal of Clinical Oncology, Cancer, and Cancer Research.
Follow along by reading the TRANSCRIPT (transcript will open in a separate window)

0:00